Results 241 to 250 of about 6,329,447 (296)

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

ÐаÑоби гаÑмонÑзаÑÑÑ Ð½Ð°Ð²ÑалÑÐ½Ð¸Ñ Ð¿ÑимÑÑÐµÐ½Ñ Ð² аÑпекÑÑ ÐµÐºÐ¾-виÑованнÑ

, 2016
M. Artenenko, O. Chepeljuk
openalex   +1 more source

ÐнедÑение CRM ÑиÑÑÐµÐ¼Ñ Ð² ÑÑÑболÑном клÑбе âТоÑноâ Ð´Ð»Ñ Ð¾Ð¿ÑимизаÑии взаимодейÑÑÐ²Ð¸Ñ Ñ Ð±Ð¾Ð»ÐµÐ»ÑÑиками

, 2018
Гасилин, Юрий
openalex   +1 more source

Ketamine for Analgosedation in Critically Ill Mechanically Ventilated Children: A Systematic Review and Meta-Analysis. [PDF]

Crit Care Explor
Zorko DJ, Zou D, Sharif S, Dearness K, Rochwerg B, Parker MJ.   +5 more
europepmc   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

Hemostatic net in cervical and facial surgeries: evidence from a systematic review and meta-analysis. [PDF]

Acta Cir Bras
Gonçalves FG, Silva LDD, Sampaio ECDF, Almeida AS, Terada BD, Malacarne GA, Friedmann ID, Moreira MR, Gemperli R, Camargo CP.   +9 more
europepmc   +1 more source

NKCC1: A key regulator of glioblastoma progression

Molecular Oncology, EarlyView.
Glioblastoma (GBM) progression is driven by disrupted chloride cotransporter homeostasis. NKCC1 is highly expressed in stem‐like, astrocytic, and progenitor cells, correlating with earlier recurrence, while overall survival remains unaffected. NKCC1 serves as a prognostic marker and potential therapeutic target, linking chloride transporter imbalance ...
Anja Thomsen, Diana Freitag, Madlen Haase, Christian Senft, Falko Schwarz, Silke Keiner   +5 more
wiley   +1 more source

ÐÑÑледование ÑоÑиалÑного довеÑÐ¸Ñ Ð² межлиÑноÑÑнÑÑ Ð¾ÑноÑениÑÑ (на пÑимеÑе ÑÑÑденÑеÑÐºÐ¸Ñ Ð³ÑÑпп)

, 2018
Писарева, Кристина
openalex   +1 more source

IPr*^BndiNHC - sterically adaptable benzyl-linked dinuclear N-heterocyclic carbenes. [PDF]

Dalton Trans
Halikowska-Tarasek K, Dziuk B, Szostak R, Szostak M, Bisz E.   +4 more
europepmc   +1 more source

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source